Your browser doesn't support javascript.
loading
Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
Sarfaty, Michal; Hall, Peter S; Chan, Kelvin K W; Virik, Kiran; Leshno, Moshe; Gordon, Noa; Moore, Assaf; Neiman, Victoria; Rosenbaum, Eli; Goldstein, Daniel A.
Afiliação
  • Sarfaty M; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: michalchen1@gmail.com.
  • Hall PS; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
  • Chan KKW; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada.
  • Virik K; Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Kingston, Ontario, Canada; Department of Oncology, Queen's University, Kingston, Ontario, Canada.
  • Leshno M; Coller School of Management, Tel Aviv University, Tel Aviv, Israel.
  • Gordon N; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.
  • Moore A; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.
  • Neiman V; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Rosenbaum E; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Goldstein DA; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.
Eur Urol ; 74(1): 57-62, 2018 07.
Article em En | MEDLINE | ID: mdl-29576265

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article